Sign inJoin waitlistJoin the waitlist

Mark Yarchoan

Physician · Johns Hopkins School of Medicine

Credentials: · · · · ·

History

Johns Hopkins School of Medicine
Present

Medical Oncology
2015–2017
Internal Medicine
2012–2015
Johns Hopkins School of Medicine
2008–2012

Research

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Review · Annals of Oncology · 2019 · 2,112 citations
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Hepatology · 2023 · 1,671 citations
Targeting neoantigens to augment antitumour immunity
Review · Nature reviews. Cancer · 2017 · First of 5 authors · 721 citations

Elizabeth Jaffee
63 papers
WH
Won Jin Ho
40 papers · 3 as a fellow
MB
Marina Baretti
37 papers · 28 as a resident
Robert Anders
32 papers
Nilofer Azad
27 papers
Daniel Laheru
20 papers
NZ
Neeha Zaidi
19 papers · 1 as a fellow
DZ
Daniel Zabransky
15 papers · 4 as a fellow
Daniel Shu
13 papers · 11 as a fellow
MN
Mari Nakazawa
11 papers · 8 as a fellow
RB
Richard Burkhart
11 papers
AK
Amy Kim
10 papers

Grants

Neoadjuvant Immunotherapy Platform Study Reveals Mechanisms of Response in Hepatocellular Carcinoma (HCC)
National Cancer Institute · R01
Contact PI · $2M · Johns Hopkins University
2024–2029
Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)
National Cancer Institute · R01
Contact PI · $1.9M · Johns Hopkins University
2024–2029
Neoantigen-Specific T Cell Responses for Fibrolamellar Hepatocellular Carcinoma
National Cancer Institute · R01
Contact PI · $3.6M · Johns Hopkins University
2022–2027

Clinical trials

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Principal investigator · Active not recruiting · Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2021–2030
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
Principal investigator · Recruiting · Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020–2034